Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of ...

Relay Therapeutics gets US FDA Breakthrough Therapy Designation for zovegalisib to treat advanced breast cancer: Cambridge, Massachusetts Thursday, February 5, 2026, 16:00 Hrs [IS ...

The BTD for zovegalisib is supported by data from the Phase I/II ReDiscover trial.

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Relay Therapeutics, Inc. is the next best ...

The 55 meters shapes up as the must‑watch event in North 2, Group 3, with a potential photo finish on the horizon. Middletown ...

Relay Therapeutics shares were 9% higher, at $8.85, after the company said the Food and Drug Administration has granted Breakthrough Therapy Designation to zovegalisib in combination with fulvestrant ...

Milan Cortina 2026 adds ski mountaineering, women's large hill, women's doubles luge, dual moguls and other mixed events.

While all Olympic athletes are expected to play and perform under pressure, Canada’s historical successes at the Winter Games ...

In 2025 alone, the agency issued over 50 oncology approvals [1], but the real story is the aggressive pivot toward targeted therapies for high-unmet-need solid tumors. That momentum has accelerated in ...

The production line, jointly developed by the Institute of Coal Chemistry of the Chinese Academy of Sciences and Shanxi ...